FGFR2 and cholangiocarcinoma: In recent years, multiple phase II clinical trials that have explored FGFR inhibitors in CCA have reported interesting results, with some of these studies also leading to the FDA approval of pemigatinib and infigratinib in previously treated patients that harbor FGFR2 fusion or rearrangement [47,48].